Natco Pharma Reports 61% Drop in Q2 Profit, Declares Interim Dividend
Natco Pharmas Q2 profit plummets to ₹203 crore, down 60.8% from last year, with significant revenue decline.
Mumbai, November 13 (Daily Kiran) : Natco Pharma has announced a significant decline in its profits for the second quarter of fiscal year 2026-27, reporting a 60.8% drop to ₹203 crore. This marks a stark contrast to the ₹518 crore profit recorded during the same period last year.
In a filing to the stock exchange, the company revealed that its operational revenue also faced a substantial decline, falling 29% from ₹1,363 crore last year to ₹967 crore this quarter.
The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) plummeted by 55.4%, totaling ₹258.3 crore compared to ₹579 crore in the previous year. Consequently, the EBITDA margin decreased to 26.7%, a drop of 15.8% from the 42.5% margin reported last fiscal year.
Additionally, other income saw a significant reduction, falling from ₹100 crore last year to just ₹52 crore in the current quarter.
In light of these results, Natco Pharma’s Board of Directors declared a second interim dividend of ₹1.25 per equity share with a face value of ₹2 for the fiscal year 2026-27. The record date for identifying eligible shareholders is set for November 19, 2026, with payments commencing on November 27, 2026.
Following the announcement, Natco Pharma’s shares closed at ₹808 on the National Stock Exchange (NSE), reflecting a slight decline. However, the stock has yielded a 2.39% return over the past year, despite experiencing a drop of over 30% in the last six months.
